Singapore Institute of Technology
Browse

File(s) stored somewhere else

Please note: Linked content is NOT stored on Singapore Institute of Technology and we can't guarantee its availability, quality, security or accept any liability.

Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab

Version 2 2024-06-03, 07:10
Version 1 2024-05-31, 06:08
journal contribution
posted on 2024-06-03, 07:10 authored by Choon Guan Chua, Gin Tsen Chai, Xin Rong Lim, Mona Manghani, Pui Lam Bernard LeungPui Lam Bernard Leung, Li Wearn Koh

Anti-melanoma differentiation-associated 5 gene autoantibody (anti-MDA5 Ab) positive dermatomyositis (DM) with rapidly progressive interstitial lung disease (RP-ILD) is a severe and difficult-to-treat form of autoimmune myositis with unfavourable 6-month survival rates. We report a case of refractory anti-MDA5 DM RP-ILD that improved after daratumumab, a human monoclonal antibody targeting CD38-positive plasma cells.

History

Journal/Conference/Book title

Clinical and Experimental Rheumatology

Publication date

2024-02-01

Version

  • Published

Rights statement

This is the publisher's PDF version of: Chua, C. G., G. T. Chai, X. R. Lim, M. Manghani, B. P. L. Leung, and L. W. Koh. 2024. Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab. Clin Exp Rheumatol 42: 460-461. https://doi.org/ 10.55563/clinexprheumatol/monpb6

Corresponding author

Dr. Choon-Guan Chua, Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital. E-mail: choon_guan_chua@ttsh.com.sg

Usage metrics

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC